China’s Taikang Investment has led a US$32 million series B round in EOC Pharma Group, an oncology-focused development company, through its healthcare and consumer industry-focused Shandong State-owned Taikang Industry Development Fund.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?